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DNAzyme for TGF-b suppressed extracellular matrix accumu-
lation in experimental glomerulonephritis.
Background. We developed an electroporation-mediated
gene transfer method targeting glomerular mesangial cells. In-
jecting DNA solution via renal artery followed by electric pulses
using tweezers-type electrodes could result in efficient trans-
fection in mesangial cells. Therefore, this gene transfer system
opened a feasible strategy to manipulate the function of several
cytokines and growth factors in mesangial cells. Recently, a new
generation of catalytic nucleic acid composed of DNA, named
DNA enzyme (DNAzyme), has been developed.
Method. We generated a DNAzyme (TGFDE) targeting
transforming growth factor-b1 (TGF-b1), and examined the
therapeutic effect of TGFDE in vitro and in vivo.
Results. In cultured rat mesangial cells, treatment with
TGFDE blocked TGF-b1 mRNA expression, and thereby sup-
pressed type I collagen mRNA expression. Next, we introduced
TGFDE or scrambled DNAzyme (TGFSCR) into anti-Thy-1
model of nephritic rats by electroporation 3 days after disease
induction. Northern blot analysis and immunohistochemical
staining demonstrated that glomerular message and protein ex-
pression of TGF-b1, a-smooth muscle actin (a-SMA), and type
I collagen were suppressed in TGFDE-transfected nephritic
rats compared with untreated nephritic rats and TGFSCR-
transfected rats on day 7. Consequently, we observed significant
reduction in glomerular matrix score in TGFDE-transfected
nephritic rats.
Conclusion. Inhibition of TGF-b1 expression by electropora-
tion-mediated DNAzyme transfer might be useful for the ther-
apy of glomerulonephritis.
Glomerular mesangial cell proliferation and extracel-
lular matrix (ECM) accumulation are central features of
numerous experimental and human glomerular diseases.
These processes are thought to play an important role in
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the development of glomerulosclerosis and renal failure.
Transforming growth factor-b (TGF-b) regulates biologic
processes such as cell proliferation, differentiation, and
immunologic reaction. One of the most important bio-
logic actions of TGF-b is the regulation of ECM accu-
mulation [1]. Previous reports strongly suggest that the
inhibition of mesangial TGF-b expression should be one
of the crucial therapeutic strategies to prevent the pro-
gression of renal fibrosis.
Recently, we developed a new gene transfer system by
electroporation in vivo; infusing DNA solution via re-
nal artery followed by electric pulses using tweezers-type
electrode could introduce genes into mesangial cells in
almost all of the glomeruli [2]. Electroporation is free
from oncogenicity, immunogenicity, and cytotoxicity of
viral vectors. In addition, electroporation-mediated gene
transfer technique resulted in significantly higher trans-
fection efficiency than hemaglutinating virus of Japan
(HVJ) liposome method [2].
A new generation of catalytic nucleic acid composed
of DNA, named DNAzyme, has been developed. These
DNAzymes can potentially cleave RNA at any purine-
pyrimidine junction and offer greater substrate specificity
than hammerhead ribozymes [3, 4]. This study examined
whether electroporation-mediated DNAzyme transfer
could inhibit the TGF-b1 action in mesangial cells in vivo.
METHODS
Design of DNAzyme
Sequences of DNAzyme (TGFDE) for rat TGF-b1
used in the present study were 5′-CGAGGGCGGCAG
GCTAGCTACAACGAGGGGGAGGCT-3′ (3′ thymi-
dine inverted is italic, catalytic domain is underlined)
(Bex, Tokyo, Japan). TGFDE has nine and eleven nu-
cleotide arms flanking the 15 nucleotide catalytic do-
main (underlined), which was designed to target the
translational site adenine-uracil-guanine (AUG) in rat
TGF-b1 mRNA. For resistance to 3′-to-5′ exonuclease
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Fig. 1. The effect of DNAzyme in cultured rat mesangial cells. North-
ern blot analysis demonstrated DNAzyme, TGFDE, blocked fetal calf
serum (FCS)-induced transforming growth factor-b1 (TGF-b1) and
type I collagen expression, while scrambled oligonucleoside, TGFSCR,
had no effect. GAPDH is glyceraldehyde-3-phosphate dehydrogenase.
digestion, the 3′ terminus of the molecule was capped
with an inverted 3′-3′-linked thymidine (italics). The nu-
cleotide sequence in each arm of TGFDE was scram-
bled without altering the catalytic domain (TGFSCR).
TGFSCR sequences were 5′-GGGGGAGGCGGCTAG
CTACAACGACGAGGGCGGCAT-3′ (3′ thymidine
inverted is italic, catalytic domain is underlined).
Effects of TGFDE in cultured mesangial cells
To examine the effects of TGFDE on TGF-b1 and
type I collagen expression on mesangial cells, subcon-
fluent rat mesangial cells [5] were growth arrested with
0.4% fetal calf serum (FCS). Quiescent subconfluent cells
were treated with adding TGFDE or TGFSCR (1 and 5
lmol/L) for 24 hours. Treated cells were then stimulated
with 20% FCS for 8 hours and TGF-b1 and type I colla-
gen mRNA expression was determined by Northern blot
analysis. TGFDE blocked FCS-induced TGF-b1 and type
I collagen mRNA expression on rat mesangial cells, while
TGFSCR had no effect (Fig. 1).
Experimental design in anti-Thy-1 nephritis
To determine the therapeutic effect of TGFDE on
mesangial proliferative glomerulonephritis, we trans-
ferred TGFDE into nephritic rats by electroporation
in vivo [2]. All procedures were handled in a humane
fashion in accordance with the guidelines of the Animal
Committee of Osaka University. Six-week-old male
Sprague-Dawley rats were anesthetized by intraperi-
toneal injection of pentobarbital (50 mg/kg) and anti-
Thy-1 model of glomerulonephritis was induced by an
intravenous injection of anti-Thy-1 monoclonal antibody,
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Fig. 2. Inhibition of transforming growth factor-b1 (TGF-b1), a-
smooth muscle actin (a-SMA), and type I collagen mRNA in nephritic
glomeruli by TGFDE. RNA was extracted from isolated glomeruli of
normal kidney or untreated, TGFDE-treated and TGFSCR-treated
nephritic kidney. Northern blot was probed for TGF-b1, aSMA, type I
collagen, or glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
1-22-3 (5 mg/kg) [6]. On day 3, TGFDE or TGFSCR
(200 lg) was transferred into nephritic rats (four rats in
each group).
On day 7, treated left kidneys and untreated contralat-
eral right kidneys were perfused with cold autoclaved
phosphate-buffered saline (PBS), and samples of tissues
for light microscopy were fixed with 4% paraformalde-
hyde overnight and dehydrated through a graded ethanol
series and embedded in paraffin. Histologic sections
(2 lm) of the kidneys were stained with periodic acid-
Schiff (PAS) reagent. Tissues for a-smooth muscle actin
(a-SMA) immunostaining were fixed in methyl Carnoy’s
solution. For glomerular RNA preparations, glomeruli
were isolated from the pooled remaining renal tissue by a
standard sieving method. The experiments were repeated
three times.
RESULTS
Effect of TGFDE on TGF-b a-SMA and collagen I
expression in vivo
To examine the effects of TGFDE in vivo, we trans-
ferred TGFDE or TGFSCR into nephritic rats on day 3,
and examined glomerular mRNA levels on day 7. North-
ern blot analysis demonstrated that TGF-b1 mRNA
levels were markedly increased in untreated and
TGFSCR-treated nephritic kidneys. In contrast, TGFDE
transfection reduced the levels of TGF-b1 mRNA. In
addition, glomerular mRNA levels of a-SMA and type
I collagen were increased in untreated and TGFSCR-
treated kidneys, while TGFDE transfection inhibited the
a-SMA and type I collagen expression (Fig. 2). Laser
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Fig. 3. Inhibition of glomerular expression of transforming growth factor-b (TGF-b) by TGFDE. Representative photomicrographs show the
immunohistochemical staining for TGF-b in untreated (A), TGFDE-treated (B), and TGFSCR-treated (C) nephritic kidney (×200). TGFDE (D)
significantly suppressed glomerular TGF-b expression (1.69 ± 0.49, 0.81 ± 0.47, and 1.73 ± 0.63 in untreated, TGFDE, and TGFSCR, respectively).
∗P < 0.001.
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Fig. 4. Inhibition of glomerular expression of a-smooth muscle actin (a-SMA) by TGFDE. Representative photomicrographs show the immunohis-
tochemical staining for a-SMA in untreated (A), TGFDE-treated (B), and TGFSCR-treated (C) nephritic kidney (×200). TGFDE (D) significantly
suppressed glomerular a-SMA expression (2.17 ± 0.72, 0.72 ± 0.42, and 2.14 ± 0.66 in untreated, TGFDE, and TGFSCR, respectively). ∗P < 0.001.
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Fig. 5. Inhibition of glomerular extracellular matrix (ECM) accumulation by TGFDE. Representative photomicrographs show periodic acid-
Schiff (PAS) staining in untreated (A), TGFDE-treated (B), and TGFSCR-treated (C) nephritic kidney (×200). Glomerular matrix score (D) was
significantly reduced in TGFDE-treated kidneys compared with untreated and TGFSCR-treated kidneys (2.85 ± 0.78, 1.97 ± 0.72, and 2.68 ± 0.73
in untreated, TGFDE, and TGFSCR, respectively). ∗P < 0.001.
densitometric analysis revealed that TGF-b1 and type I
collagen mRNA in glomeruli from nephritic rats treated
with TGFDE was reduced to 47% and 34% of those in
untreated disease control, respectively.
TGF-b1 (Fig. 3) and aSMA (Fig. 4) protein ex-
pression was studied by immunohistochemistry using
antihuman TGF-b1 polyclonal antibody (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) and anti-a-SMA
monoclonal antibody (Immunotech, Marseilles, France),
respectively. Expression of TGF-b1 was up-regulated
in the glomeruli from nephritic rats, and this expres-
sion was significantly suppressed in those rats treated
with TGFDE (Fig. 3D). In contrast, the level of TGF-
b1 expression was unchanged in TGFSCR-treated rats.
We also observed a-SMA expression in the glomeruli
of untreated and TGFSCR-treated kidneys. However,
immunostaining of a-SMA was significantly weak in
TGFDE-treated kidney (Fig. 4D).
DISCUSSION
Effect on glomerular matrix accumulation
To determine the effect on the histological changes in
nephritic kidneys, histologic analysis was performed us-
ing PAS staining. PAS staining showed marked ECM ac-
cumulation in untreated and TGFSCR-treated kidneys.
In contrast, TGFDE transfection reduced ECM accu-
mulation (Fig. 5). The degree of glomerular matrix ac-
cumulation was determined as the percentage of each
glomerulus occupied by mesangial matrix. Glomerular
matrix score was significantly reduced in TGFDE-treated
kidneys compared with untreated and TGFSCR-treated
kidneys. We further examined the effect of TGFDE on
glomerular platelet-derived growth factor (PDGF) ex-
pression by reverse transcription-polymerase chain re-
action (RT-PCR), and observed no differences between
three groups (data not shown). In addition, glomerular
cell number was not affected (79.5 ± 9.7, 75.9 ± 8.2, and
80.6 ± 9.3 in untreated, TGFDE, and TGFSCR, respec-
tively). TGF-b is considered necessary for the glomerular
remodeling. We examined the healing process of mesan-
giolysis and the later stage of the disease in the treated
rats. TGFDE transfection did not interfere with the ini-
tial injury in the anti-Thy-1 model, because treated and
untreated kidney had equivalent mesangiolysis. On the
contrary, the healing process seemed accelerated in
TGFDE-treated kidney probably due to the suppression
of excessive ECM deposition.
In order to inhibit the gene expression by cleav-
age of the target mRNA, antisense oligonucleotides has
been adopted [7]. We compared the effect of TGFDE
with antisense oligonucleotides. Treatment with antisense
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oligonucleotide (200 lg) for TGF-b1 also reduced
glomerular TGF-b1 and type I collagen mRNA ex-
pression to 53% and 41% of untreatment, respectively.
TGFDE was not less effective than antisense olignu-
cleotides in treating nephritic disease was consistent with
the previous report [4]. However, the effect of anti-
sense may be transient, because RNase H bases antisense
mechanism on the hydrolysis of RNA-DNA duplex [8]. In
contrast, the 3′ terminus of TGFDE was capped with an
inverted 3′-3′-linked thymidine for resistance to 3′-to-5′
exonuclease digestion, because phosphorothioate mod-
ified oligonucleotides may hamper the cellular function
[4].
We should establish the safety of this method prior to
clinical application. However, we observed no damage in
glomeruli and tubular epithelial cells when TGFDE was
transferred into normal kidney on histologic examina-
tion. In addition, there was no difference between normal
and TGFDE-treated rats in the serum lactate dehydroge-
nase (LDH) levels (117.5 ± 26.7 and 129.3 ± 29.2 in un-
treated and TGFDE, respectively), suggesting no major
toxicity of electroporation-mediated TGFDE transfer.
CONCLUSION
Our study demonstrates that DNA injection via renal
artery followed by electroporation could be a powerful
therapeutic tool in vivo. The molecular intervention by
DNAzyme for TGF-b may be a promising strategy for
treatment of glomerular diseases.
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